Ubrogepant Is Not Associated With Clinically Meaningful Elevations of Alanine Aminotransferase in Healthy Adult Males

Autor: Wendy Ankrom, Phung Bondiskey, Chi‐Chung Li, John Palcza, Wen Liu, Marissa F. Dockendorf, Catherine Matthews, Deborah Panebianco, Tom Reynders, John A. Wagner, Abhijeet Jakate, Sofie Mesens, Walter K. Kraft, Eugene E. Marcantonio
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Zdroj: Clinical and Translational Science, Vol 13, Iss 3, Pp 462-472 (2020)
Druh dokumentu: article
ISSN: 1752-8062
1752-8054
DOI: 10.1111/cts.12728
Popis: Ubrogepant is a novel, oral calcitonin gene‐related peptide (CGRP) receptor antagonist intended for the acute treatment of migraine attacks. Ubrogepant has a chemical structure distinct from previous small‐molecule CGRP receptor antagonists that were associated with elevated serum alanine aminotransferase (ALT) in clinical trials. Here, we report overall and hepatic safety data from two placebo‐controlled phase I trials of ubrogepant, spray‐dried oral compressed tablet (SD‐OCT) in healthy male volunteers. Trial A was a pharmacokinetic (PK) trial of single (100–400 mg) and multiple (40–400 mg) ascending doses. Trial B was a dedicated hepatic safety trial assessing daily use of ubrogepant 150 mg for 28 days. Serum ALT (as hepatotoxicity biomarker) and PK data are reported. Ubrogepant was well‐tolerated in both trials, with a low incidence of adverse events that did not differ greatly from placebo. Changes in mean ALT levels were minimal and similar to placebo. Over 28 days of treatment, the mean percentage change in ALT from baseline was
Databáze: Directory of Open Access Journals
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje